This case highlights the potential of ALK-targeted therapy in treating rare SMARCA4-deficient tumors and suggests a potential synergistic relationship between SMARCA4 deletion and ALK rearrangement in NSCLC. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.